Pouillon, Lieven
Travis, Simon http://orcid.org/0000-0002-2690-4361
Bossuyt, Peter http://orcid.org/0000-0003-4027-7365
Danese, Silvio http://orcid.org/0000-0001-7341-1351
Peyrin-Biroulet, Laurent http://orcid.org/0000-0003-2536-6618
Article History
Accepted: 18 March 2020
First Online: 17 April 2020
Change Date: 5 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published: https://doi.org/10.1038/s41575-020-00409-x.
Competing interests
: L.P. received personal fees from Abbvie, Ferring, Takeda; and advisory board fees from Takeda. S.T. received research support from AbbVie, Buhlmann, Celgene, International Organization for the Study of Inflammatory Bowel Disease, Janssen, Lilly, Takeda, UCB, Vifor and Norman Collisson Foundation; consulting fees from AbbVie, Allergan, Amgen, Arena, Asahi, Astellas, Biocare, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Buhlmann, Celgene, Chemocentryx, Cosmo, Enterome, Ferring, Giuliani SpA, GSK, Genentech, Gilead, Immunocore, Immunometabolism, Indigo, Janssen, Lexicon, Lilly, Merck, MSD, Neovacs, Novartis, NovoNordisk, NPS Pharmaceuticals, Pfizer, Proximagen, Receptos, Roche, Sandoz, Sensyne, Shire, Sigmoid Pharma, SynDermix, Takeda, Theravance, Tillotts, Topivert, UCB, VHsquared, Vifor and Zeria; speaker fees from AbbVie, Amgen, Biogen, Ferring, Janssen, Shire and Takeda; and declares no stock or share options. P.B. received educational grants from AbbVie, Mundipharma, Pfizer and Janssen; speaker fees from AbbVie, Takeda and Pfizer; and advisory board fees from Hospira, Janssen, MSD, Mundipharma, Roche, Pfizer, Takeda, Sandoz and Pentax. S.D. has served as a speaker, a consultant and an advisory board member for Abbvie, Ferring, Hospira, Johnson & Johnson, Merck, Millennium Takeda, Mundipharma, Pfizer, Tigenix, UCB Pharma and Vifor. L.P.-B. received personal fees from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera and Theravance; grants from Abbvie, MSD and Takeda; and stock options from CTMA.